Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2021-05-26
Buyer: Oslo Universitetssykehus HF (hovedenhet)
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 13218662 NOK

Technical requirements: Kjernefasilitet for genomikk, OUS, (the Genomics Core Facility, Oslo University Hospital) will procure a sequencer for high throughput sequencing (HTS)/next generation sequencing, suited for expanded cancer panels, transcriptome sequencing, exome sequencing and genome sequencing for different issues. The instrument will be used to analyse cancer samples for research purposes and for stratification of cancer patients to clinical studies as part of the InPred-infrastructure.
Kjernefasilitet for genomikk, OUS, (the Genomics Core Facility, Oslo University Hospital) will procure a sequencer for high throughput sequencing (HTS)/next generation sequencing, suited for expanded cancer panels, transcriptome sequencing, exome sequencing and genome sequencing for different issues. The instrument will be used to analyse cancer samples for research purposes and for stratification of cancer patients in clinical studies as part of the InPred-infrastructure.
The genomics core facility will need both expanded cancer panels, transcriptome sequencing, exome sequencing and genome sequencing for different issues, including analysis of cancer samples for stratification in clinical studies as part of the InPred-infrastructure. To ensure a quick response time for study-related cancer samples it is important that they can be run simultaneously (on the same flow cell). The core facility needs very large capacity, as samples for many different purposes must be sequenced and analysed in addition to study-related samples. Also, for other purposes it is extremely important that the response time and analysis time are kept down. This also includes primary and secondary data analysis through the use of Dragen, which is a highly specialised and extremely quick analysis platform for sequencing data. Therefore, the data generated by the sequencer must be directly compatible with the Dragen platform. The requirement highlights the need for flexibility in regard to whether analysis time or capacity should be prioritised, as there will be instances where urgent samples must be processed. The instrument must be able to handle different protocols in order to cover the different purposed that the samples are sequenced for. The instrument must also be flexible for reading lengths, from short reading lengths (35 bp) to long reading lengths (500 bp), as this will be advantageous in relation to costs, analysis time and protocols. In relation to cancer samples from the InPred-infrastructure, the sequencing system must be fully compatible with the Tru Sight Oncology 500 (TSO500) gene panel will full support of the panel supplier. This gene panel, due to sensitivity, specificity and response time, has been validated and implemented for the InPred-infrastructure for use in the IMPRESS national cancer study. The sequencing data generated for the TSO500 panel must be compatible for downstream analysis with Illumina's TSO500 pipelines (docker based) and the Dragen platform. The results from the downstream analysis come in FASTQ, BAM and VCF format, which is the standard for the software used for analysis and interpretation of gene variants and gene expression. There is a need for < 48 hours response time from when OUS contacts the service provider until the service technician is in place. This is very important in order to maintain delivery deadlines. Downtime must, thus, be limited. There must be a similar sequencer in the immediate area that can be used as a spare machine in case of downtime. As part of the NorSeq consortium we have a contract with the sister core facility located at Ullevål Hospital, providing us access to a spare instrument. The basis is that Illumina is the only supplier that, due to technical reasons, can deliver in accordance with the requirements. The prior information notice is founded in-line with the Public Procurement Regulations § 21-5. The terms in PPR § 13-4 (2) and 13-1 (5) are considered fulfilled, as well as the value of the full service contract and a contract for consumables for the lifetime of the equipment. Due to space limitations in the laboratory, the footprint of the instrument must not be larger than 2.4 m in width and 2.8 m in depth (including minimum clearance).


Winner: Illumina Norway AS
Award value: 13218662